Justin H. Johannesen
Robert J. Morgan
Mohammed M. Algodi
Andrea Mignatti
David M. Loeb
<p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis, and has used this model to perform preclinical testing of novel agents that can interfere with this process. More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma migration, invasion, and metastasis. Dr. Loeb is also studying the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA. More recently, the laboratory has developed an interest in targeting the metabolic reprogramming associated with metastasis as a way to prevent the outgrowth of distant metastases from disseminated tumor cells.</p>
<p> </p>
<p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He serves as the local PI for a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. Finally, as an offshoot of his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents, and young adults with sarcomas.</p>
<p>Dr. Loeb is a leading pediatric oncologist and NIH-funded researcher. He has extensive expertise in sarcoma research and clinical care and is a bone marrow transplantation specialist. Dr. Loeb’s research spans the spectrum from basic and translational studies to clinical trials using novel therapies.</p>
<p>Dr. Loeb's PubMed bibliography can be found here: </p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1fiIspwqfwUE46/bibliography/5…;
<p>David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children’s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer.</p><p>Dr. Loeb earned his Bachelor of Arts in biology in 1987 at Johns Hopkins University. In 1993, he received his Doctor of Philosophy in Pathology and, in 1994, his Doctor of Medicine at Columbia University. In 1994, he also began an internship in Pediatrics at the Johns Hopkins University School of Medicine, followed by a residency in 1995 and a fellowship in Pediatric Hematology Oncology at the same institution.</p><p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis and has used this model to perform preclinical testing of novel agents that can interfere with this process. One area of focus is the metabolic differences between cancer cells and normal cells, and between metastases and the primary tumor, with the intention of targeting these differences therapeutically. More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma and osteosarcoma migration, invasion and metastasis. Dr. Loeb also studies the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA.</p><p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He has also directed a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. Stemming from his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents and young adults with sarcomas. Dr. Loeb’s original research, based on his clinical and laboratory studies, has been published in multiple journals and books.</p><p>Dr. Loeb has been a recipient of many awards, including the Director’s Teaching Award in Clinical Science from Sidney Kimmel Comprehensive Cancer Center in 2006, 2010 and 2015, and The Justin Straus Chordoma Research Award in 2009.</p>
Carlos A. Gongora
<p><span style="color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', 'Fira Sans', Ubuntu, Oxygen, 'Oxygen Sans', Cantarell, 'Droid Sans', 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Lucida Grande', Helvetica, Arial, sans-serif;">Carlos A Gongora MD is a Cardiologist, Cardio-Oncologist, Cardiac Imager, and Researcher at Montefiore Medical Center. He is a physician educated in Mexico and a graduate of the Faculty of Medicine at the Benemerita Universidad Autonoma de Puebla (BUAP). After studying at the BUAP he worked for 1 year as a primary care physician at a rural clinic in a small community in Puebla, Mexico. After that, he moved to the USA and worked as a program coordinator in a public health project in Boston, MA, promoting cardiovascular health and healthy eating. Then, he completed two years of cardiovascular research at the Cardiovascular Research Foundation, where he published and presented his research in various international conferences and received an award of excellence for his research. He finished his Cardiology fellowship in June of 2020 at Mount Sinai West and Morningside Hospitals. During his residency and fellowship, he continued with his cardiovascular research and has worked in a public health program in the Bronx. Also, during his cardiology fellowship he developed, presented and published different cardiovascular research projects. Due to his hard work, he was chosen as Chief Cardiology Fellow. During the beginning of the COVID-19 pandemic in New York City, Dr. Gongora took care of critically ill COVID-19 patients with cardiac comorbidities in the Cardiac Care Unit. He participated in international conferences to discuss the latest observations, advances and therapies in hospitalized patients with COVID-19. He lastly finished an Advanced Cardiac Imaging and Cardio-Oncology Fellowship at the Massachusetts General Hospital and Harvard Medical School. Also he completed courses in Epidemiology and Biostatistics at the Harvard School of Public Health. While in Boston, Dr. Gongora has been involved in projects focusing on cardiotoxicity associated with immune therapies and anthracyclines among patients with cancer. Additionally, he has worked on projects focusing on medical therapy for patients with COVID-19 and their cardiac involvement.</span></p>
Aryeh Z. Abelow
Anna Y. Zolotnitskaya
<p>Anna Zolotnitskaya, MD, is Medical Director, Pediatric Dialysis at the Children’s Hospital at Montefiore Einstein and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Zolotnitskaya’s clinical focus is on pediatric dialysis and pediatric renal transplantation. She leads a multidisciplinary dialysis team that provides patient-centered, evidence-based care for children and young adults with end-stage kidney disease. </p><p>After obtaining her Doctor of Medicine at St. Petersburg Pediatric Academy in St. Petersburg, Russia, in 1983, Dr. Zolotnitskaya completed her pediatrics internship at the same institution in 1984. She remained there to complete her pediatrics residency in 1989, before completing an additional pediatrics residency at Soroka Medical Center in Beer-Sheva, Israel, in 1994. Following this, Dr. Zolotnitskaya completed a pediatric nephrology fellowship at Montefiore Einstein in 1998, followed by an additional pediatrics residency at Columbia University College of Physicians and Surgeons, St. Luke’s-Roosevelt Hospital in 2001. </p><p>Dr. Zolotnitskaya has been principal investigator and co-investigator in clinical trials that investigate medications employed for the care of children with advanced chronic kidney disease. Her work has been published in numerous peer-reviewed journals and abstracts, and she has given several invited presentations. She is also a reviewer for the <em>Journal of Pediatrics: Clinical Practice</em>. </p><p>Dr. Zolotnitskaya is board certified by the American Board of Pediatric Nephrology, the American Board of Pediatrics and the Israeli Board of Pediatrics. She is a member of the American Academy of Pediatrics, the American Society of Nephrology and the American Society of Pediatric Nephrology.
</p>
Lili Zhang
Non-invasive cardiology, echocardiography, cardio-oncology, multimodality cardiovascular imaging
Cardiotoxicity of cancer therapy, immune checkpoint inhibitor myocarditis, and the application of multimodality imaging and machine-learning techniques in cardiovascular disease.
<p>Lili Zhang, MD, is Director, Cardio-Oncology Program and Assistant Professor, Cardiology at Montefiore Einstein. A non-invasive cardiologist and a cardiac imaging specialist, Dr. Zhang’s clinical focus is in Cardio-Oncology, cardiomyopathy, general cardiology, echocardiography and multimodality cardiac imaging.</p><p>In 2007, Dr. Zhang earned her Doctor of Medicine degree at Peking University, Beijing, China. Further education and postdoctoral training brought her to the U.S., completing her Master of Science in Epidemiology at Johns Hopkins Bloomberg School of Public Health in 2011. She then came to Einstein, completing her residency in internal medicine in 2015 and her fellowship in cardiology in 2018. In 2019, Dr. Zhang completed her fellowship in Cardio-Oncology and cardiac imaging at Massachusetts General Hospital.</p><p>Dr. Zhang’s research focuses on cardiotoxicity of cancer therapy, immune checkpoint inhibitor myocarditis, cardiovascular care and the application of multimodality imaging and machine-learning techniques in cardiovascular disease. Her research experience includes retrospective studies, prospective cohorts (ARIC and CHS), large multi-cohort consortiums (CHARGE and PAGE consortiums), randomized clinical trials (PROMISE trial), and international collaborative registries (international immune checkpoint inhibitor myocarditis registry and Global Cardio Oncology Registry). She has shared her work through more than 60 manuscripts in peer-reviewed journals and abstract publications.</p><p>Dr. Zhang is board certified in Internal Medicine and Cardiovascular Disease. She is a Fellow of the American College of Cardiology, and is a member of the American Heart Association and the international Cardio-Oncology Society. In 2021, she was awarded the Glorney-Raisbeck Junior Faculty Research Award in Cardiovascular Disease by New York Academy of Medicine.</p>